Call For Papers: Intratumoral Immunotherapy with Nanoparticles

This Molecular Pharmaceutics Virtual Special Issue is dedicated to intratumoral immunotherapy enabled through nanotechnologies, drug delivery and formulation research performed within academia and industry.

Nanotechnology approaches have opened the door to interface with the tumor microenvironment—to train the body’s own immune system to fight tumors and establish long-lasting immune memory. A number of immunomodulatory nanoparticles, biologics, and/or materials engineered to delivery immunostimulatory agents have been developed. The development pipeline is moving rapidly with technologies at various pre- and clinical stages of development. This Special Issue seeks to capture nanotechnology approaches toward intratumoral therapy.

The topics in focus are:

• Immunomodulatory nanoparticles, viruses, and other biologics
• Nanotechnologies for delivery of immunomodulatory agents (e.g. STING, TLR agonists)
• Adjuvant and neoadjuvant strategies with intratumoral nanoparticles
• Immune-combination therapies, e.g., combination of intratumoral therapy with systemic immunotherapy such as checkpoint therapy
• Delivery devices, hydrogels, slow-release formulations for enhanced intratumoral immunotherapy
• Studies focused on the mechanism of action, pharmacology and safety of intratumoral immunotherapy
• Understanding nanoparticle delivery mechanisms and implications for intratumoral targeting
• Tools, computational models, and AI to study intratumoral immunotherapy enabled by nanotechnology
• Nanotechnology aimed specifically at monitoring and understanding the tumor microenvironment
• Intratumoral immunotherapy with nanoparticles combined with physical methods (radiation, cold, heat, or light).

Organizing Editors

Prof. Nicole F. Steinmetz, Lead Guest Editor
University of California San Diego, United States | Email

Prof. Hui Cai, Guest Editor
Sun Yat-sen University, China | Email

Anthony Omole, Guest Editor
University of California San Diego, United States | Email

Prof. Steven N. Fiering, Guest Editor
Dartmouth College, United States | Email

If readers have questions about contributing to this Special Issue, please contact Lead Guest Editor Nicole F. Steinmetz for more details.

Submission Information

We welcome submissions for this Virtual Special Issue through August 1, 2024. For more information on submission requirements, please visit the journal’s Author Guidelines page.

Manuscripts formatted as Research Articles, Communications, Reviews, or Perspectives will be accepted from all the relevant fields. If the paper is ready before the deadline, please feel free to submit it under the appropriate special issue title, and it will be processed normally. If extra time is needed, please contact us as soon as possible so that we might accommodate the request. Acceptance is dependent on the results of peer review.

Upon acceptance, the paper will be published on a rolling basis in a regular issue of Molecular Pharmaceutics. Once all invited articles have appeared online, they will be collected into a single Virtual Special Issue and provide the authors additional exposure. More information about the journal (such as scope and author guidelines) can be found online here.

Molecular Pharmaceutics is a hybrid subscription journal, meaning there is no publication fee to the author (also called article processing charge or APC) unless the author elects to purchase open access through our various licensing options. Visit our Open Science Resource Center to learn more about our various open access options, or contact managing.editor@mp.acs.org for more information.

How to Submit

• Log in to the ACS Paragon Plus submission site.
• Choose Molecular Pharmaceutics.
• Select your manuscript type, and, under "Virtual Special Issue Selection," choose "Intratumoral Immunotherapy with Nanoparticles."